ReviewPathogens (Basel, Switzerland)2014
Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.
Review in Pathogens (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 1 synthesis or guideline pooled it, 271 citations in OpenAlex.
- A Middle East systematic review and meta-analysis of prevalence and antibiotic susceptibility pattern in MRSA Staphylococcus aureus isolated from patients with cystic fibrosis.Journal of health, population, and nutrition · 2022Pooled it
- Intra-strain genomic microevolution and phage resistance inMicrobiology spectrum · 2026Article
- Natural Lactone-Based Quorum Sensing Inhibitors Attenuate Virulence in Pseudomonas aeruginosa.Chemistry & biodiversity · 2026Article
- Harnessing the endophytic Clavispora lusitaniae for the biogenic synthesis of ethylene glycol-capped cerium oxide nanoparticles: a green approach to combat respiratory Pseudomonas aeruginosa.Microbial cell factories · 2026Article
- Article
- Review
- Comparison of clinical and microbiological features between mucoid and non-mucoidMicrobiology spectrum · 2026Article
- Glycoside hydrolases enhance antibiotic activity againstMicrobiology spectrum · 2026Article
- High-throughput bioprinted 3D cultures for probing host-pathogen interactions in bioinspired microenvironments.RSC applied polymers · 2026Article
- Phenotypic and Metabolic Variations in High-Risk Clones of Multidrug-ResistantMicroorganisms · 2026Article
- Discovery of Novel Molecular Scaffolds to OvercomeInternational journal of molecular sciences · 2026Article
- Article
- Beyond Resistance: Phenotypic Plasticity in Bacterial Responses to Antibiotics, Oxidative Stress and Antimicrobial Photodynamic Inactivation.Molecules (Basel, Switzerland) · 2026Review
- Dual-functional quorum sensing signal synthases DspII and DspI coordinate virulence switch in Pseudomonas aeruginosa.Nature communications · 2026Article
- Culture and Adaptation of Pseudomonas aeruginosa During Early Infection in Children With Cystic Fibrosis.The Journal of infectious diseases · 2026Article
- Defence systems drive accessory genome interactions inISME communications · 2026Article
- Article
- A systematic longitudinal study of microbiome: integrating temporal-spatial dimensions with causal and deep learning models.BMC genomics · 2025Article
- The Catabolite Repression Control Protein Crc Regulates the Type III Secretion System Through the Adenylate Cyclase CyaB inMicroorganisms · 2025Article
- Attenuated Strains of Pseudomonas aeruginosa: A Promising Cell Factory for Rhamnolipid Production.Microbial biotechnology · 2025Review
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is the most prevalent pathogen of cystic fibrosis (CF) lung disease. Its long persistence in CF airways is associated with sophisticated mechanisms of adaptation, including biofilm formation, resistance to antibiotics, hypermutability and customized pathogenicity in which virulence factors are expressed according the infection stage. CF adaptation is triggered by high selective pressure of inflamed CF lungs and by antibiotic treatments. Bacteria undergo genetic, phenotypic, and physiological variations that are fastened by the repeating interplay of mutation and selection. During CF infection development, P. aeruginosa gradually shifts from an acute virulent pathogen of early infection to a host-adapted pathogen of chronic infection. This paper reviews the most common changes undergone by P. aeruginosa at each stage of infection development in CF lungs. The comprehensive understanding of the adaptation process of P. aeruginosa may help to design more effective antimicrobial treatments and to identify new targets for future drugs to prevent the progression of infection to chronic stages.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.